Replimune Group, INC Form 4 insider transactions

Sushil Patel, Chief Executive Officer and a Director of Replimune Group, Inc., sold 39,341 shares of common stock on August 10, 2026 for $12.97 per share.

Emily Luisa Hill, Chief Financial Officer of Replimune Group, Inc., sold 11,448 shares of common stock on August 10, 2026 for $12.97 per share.

Konstantinos Xynos, Chief Medical Officer of Replimune Group, Inc., sold 11,447 shares of common stock on August 10, 2026 for $12.97 per share.

Andrew Schwendenman, Chief Accounting Officer of Replimune Group, Inc., sold 7,632 shares of common stock on August 10, 2026 for $12.97 per share.

Baker Bros. Advisors Lp and 5 others reported changes in beneficial ownership of Replimune Group, Inc. common stock on August 11, 2026.

Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock at a weighted average price of $9.24.

Konstantinos Xynos, Chief Medical Officer at Replimune Group, Inc., sold 14,023 shares of common stock to cover tax withholding obligations related to Restricted Stock Units.

Replimune Group Inc. Chief Accounting Officer Andrew Schwendenman sold 7,894 shares of common stock to cover tax obligations related to RSU vesting.

Replimune Group Inc. reports a Form 4 filing detailing a transaction by Chief Commercial Officer Christopher Sarchi involving the sale of common stock to cover tax withholding obligations.

Philip Astley-Sparke, a Director at Replimune Group, Inc., reported a transaction involving the sale of 17,657 shares of common stock to cover tax withholding obligations.

Replimune Group Inc. CEO Sushil Patel sold 37,324 shares of common stock to cover tax withholding obligations related to RSU vesting.

Baker Bros. Advisors LP, a significant stakeholder, has reported the acquisition of non-qualified stock options for Replimune Group, Inc. common stock.

Chief Commercial Officer Christopher Sarchi was granted 50,000 restricted stock units and 75,000 stock options as part of long-term incentive compensation.

Director Philip Astley-Sparke was awarded 50,000 restricted stock units and 75,000 stock options as part of Replimune Group's compensation structure.

Replimune Group director Christy J. Oliger received a grant of 44,500 stock options with a ten-year term and a one-year vesting cliff.

Replimune Group's Chief Medical Officer, Konstantinos Xynos, was granted 50,000 restricted stock units and 75,000 stock options as part of executive compensation.

Director Madhavan Balachandran received 44,500 stock options with a $7.61 exercise price, scheduled to vest in April 2027.

Replimune Group's Chief Accounting Officer, Andrew Schwendenman, has been granted 36,667 restricted stock units and 55,000 stock options as part of a long-term incentive plan.

Replimune Group CEO Sushil Patel has been granted over 600,000 shares and options as part of a long-term incentive package.

Replimune Group, Inc. director Kapil Dhingra received a grant of 44,500 stock options with an exercise price of $7.61, set to vest in 2027.

Replimune Group, Inc. director Paolo Pucci received a grant of 44,500 stock options with an exercise price of $7.61, set to vest in April 2027.

Director Joseph P. Slattery received 44,500 stock options with an exercise price of $7.61, scheduled to vest in April 2027.

Director Veleka Peeples-Dyer was granted 44,500 stock options with a $7.61 exercise price, vesting in full by April 2027.

Replimune Group's Chief Financial Officer Emily Luisa Hill was granted 50,000 restricted stock units and 75,000 stock options as part of a long-term incentive package.

Replimune Group, Inc. director Dieter Weinand received a grant of 44,500 stock options with an exercise price of $7.61, vesting in full in April 2027.

Replimune Group Inc. Chief Commercial Officer Christopher Sarchi sold 6,500 shares of common stock for approximately $8.01 per share, as part of a pre-arranged trading plan.

Replimune Group, Inc. CEO Sushil Patel was granted 200,000 restricted stock units, vesting over two years.

Replimune Group's Chief Medical Officer, Konstantinos Xynos, was granted 60,000 restricted stock units, vesting over two years.

Replimune Group, Inc.'s Chief Financial Officer, Emily Luisa Hill, was granted 60,000 restricted stock units, vesting over two years.

Replimune Group's Chief Commercial Officer, Christopher Sarchi, was granted 35,000 restricted stock units, vesting over two years.